Antacid therapy of peptic ulcer: Part II An evaluation of antacids in vitro

Piper, D. W.; Fenton, Barbara H.

doi:10.1136/gut.5.6.585

Cited by 37 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Intermittent heartburn is closely associated with a reduction of pH in the oesophagus, 3 and it is generally well controlled by antacid medication. A wide range of acid‐ and pepsin‐binding antacids have long been available on prescription and for self‐medication 4 , . 5 More recently, H 2 ‐blockers have been introduced as ‘over‐the‐counter’ drugs.…”

Section: Introductionmentioning

confidence: 99%

Onset of action during on‐demand treatment with Maalox suspension or low‐dose ranitidine for heartburn

Faaij

Gerven

Jolivet‐Landreau³

et al. 1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Onset of action during on‐demand treatment with Maalox suspension or low‐dose ranitidine for heartburn

Faaij

Gerven

Jolivet‐Landreau³

et al. 1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Ant acid intake for each patient in the 2 weeks preceding entry into the trial was assessed and converted into milliequivalents neutral ising capacity using figures provided else where [9], Only 8 patients had taken 150 mEq or more daily (6 in the cimetidine group and 2 in the colloidal bismuth group). 5 of these patients healed at 3 weeks and 3 at 6 weeks.…”

Section: Initial Healingmentioning

confidence: 99%

Cimetidine and Colloidal Bismuth in Treatment of Chronic Duodenal Ulcer

Kang

Piper²

1982

Digestion

View full text Add to dashboard Cite

The aim of the study was to compare the use of cimetidine and colloidal bismuth in the initial healing of chronic duodenal ulcer and to note the recurrence rate over 1 year after healing induced by both forms of treatment. Cimetidine was administered in the dose of 200 mg three times daily and 400 mg at night and the dose of colloidal bismuth was 5 ml four times each day. 51 outpatients with chronic duodenal ulcers proven on endoscopy completed the initial study. At 3 weeks, healing was observed in 83% of the cimetidine group and 70% of the colloidal bismuth group (p > 0.10); at 6 weeks, 96% of patients in both groups had healed. 33 patients were followed up over 1 year, 16 having initially been treated with cimetidine and 17 with colloidal bismuth. 2 other patients originally treated with cimetidine were followed up for 6 months only. No further treatment was given. Endoscopy was performed at 6 and 12 months, or earlier if symptoms developed. At 6 months, 44% of patients in the cimetidine group had recurred compared to 47% in the colloidal bismuth group (p > 0.5). At 1 year, 75% of patients in the cimetidine group and 76% in the colloidal bismuth group had recurred (p > 0.5). It is concluded that both agents are equally effective in healing duodenal ulcers and the incidence of recurrence over 1 year is similar irrespective of whether the initial healing is induced with colloidal bismuth or cimetidine.

show abstract

“…Patients reporting relief of pains by meals and/or antacids were offered trisilicate tablets neutralising 8-5 mmol acid. Antacids with aluminium hydroxide, which also has a pepsin inhibitory effect (Piper and Fenton, 1964), and anticholinergic drugs were not allowed. Treatment was given for six weeks, unless complete ulcer healing as well as absence of symptoms were observed within that period.…”

Section: Methodsmentioning

confidence: 99%